Biomarkers Core (Core E)

综述：核心E-生物标记物核心。Biomarker Core支持哈佛大学的大脑老化研究 (HABS)通过处理和储存血液(血浆、血清、全血、黄油)计划项目赠款(PPG) Coat、RNA、miRNA、DNA和细胞系)和脑脊液(AIM 1)样本由临床组收集 核心(核心B)来自个人(50岁至94岁)。将对这些生物体液进行化验以产生数据 关于淀粉样蛋白b(“A”)、tau(“T”)和神经变性(“N”)(目标2)以及关于血管损伤和免疫的数据 响应因素(目标3)，供项目分析。新近建立的赤潮生物标志物核心 包括来自赠款周期1和2的373名参与者的1300多个生物流体样本(血液和脑脊液)，并将 在下一个周期储存额外的纵向样品。血液已经被加工成血浆、血清、 收集、处理和存储全血、棕黄色大衣、RNA、miRNA、DNA和细胞系以及CSF 根据最佳做法将分析前的可变性降至最低。ATN数据已使用ULTERNAL 检测AB42、NT1 tau和神经丝光(NFL)的灵敏单分子阵列(SIMOA)技术 在迄今为止的所有样本中以及修改血管损伤和免疫反应的因素数据中使用 电化学发光酶联免疫吸附试验。样本已经分发给了合作的科学家，用于更多的 化验。严格考虑样品质量和分析的敏感性、特异性和精密度 对将在下一个周期中使用的分析有信心。 Biomarker Core由一群经验丰富的翻译实验室调查人员组成，具有广泛的 在分子神经科学和神经病理学、神经学、精神病学和生物信息库方面的经验 管理层。Biomarker Core将与临床Core合作，继续进行最佳采集和现场 血液和脑脊液的处理程序，生物体液的储存和分发，生成ATN和修改 使用可用的最敏感和最可靠的方法对数据进行因子分析。为了把血浆和脑脊液连接起来 为了更好地了解血液生物标记物对大脑健康的潜在影响，我们将在 采集HABS及其附属样本中的血浆和脑脊液。根据初步数据和项目利益，在 在下一个周期，Biomarker Core将测量AB42、NT1 tau和NFL、血管损伤标记物(特别是 血管内皮生长因子相关分子)和Th1和Th2炎症标志物(例如，分别为干扰素-g和白介素4)和其他 关联的标记。它还将继续识别、评估和实施新技术和生物标记物。 为了哈布斯。生成的数据将受到质量控制，并与 用于项目1-4的分析核心。

SUMMARY: CORE E- BIOMARKER CORE. The Biomarker Core supports the Harvard Aging Brain Study (HABS) Program Project Grant (PPG) by processing and banking blood (plasma, serum, whole blood, buffy coat, RNA, miRNA, DNA and cell lines) and cerebrospinal fluid (CSF) samples (Aim 1) collected by the Clinical Core (Core B) from individuals (ages 50 to 94). Assays will be conducted on these biofluids to generate data on amyloid-b ("A"), tau ("T") and neurodegeneration ("N") (Aim 2) and data on vascular injury and immune response factors (Aim 3) for analysis by the Projects. The newly established Biomarker Core for HABS includes over 1300 biofluid samples (blood and CSF) from 373 participants in Grant Cycles 1 and 2, and will bank additional longitudinal samples over the next cycle. Bloods have been processed into plasma, serum, whole blood, buffy coat, RNA, miRNA, DNA and cell lines, and CSFs are collected, processed and stored according to best practices to minimize pre-analytical variability. ATN data has been generated using ultra- sensitive single molecule array (Simoa) technology with assays for Ab42, NT1 tau and neurofilament-light (NfL) in all samples to date as well as modifying factor data for vascular injury and immune response using electrochemiluminescence ELISA. Samples have been distributed to collaborating scientists for additional assays. Rigorous consideration of sample quality and assay sensitivity, specificity and precision have provided confidence in the assays that will be used in the next cycle. The Biomarker Core is comprised of a seasoned group of translational laboratory investigators with extensive experience in molecular neurosciences and neuropathology, neurology, psychiatry, and biorepository management. The Biomarker Core will work with the Clinical Core to continue optimal collection and on-site processing procedures for blood and CSF, bank and distribute biofluids, and generate ATN and modifying factor data using the most sensitive and reliable methods available. In order to bridge plasma with CSF and better understand the potential of blood biomarkers of brain health, we will generate data in simultaneously collected plasma and CSF in HABS and affiliated samples. Based on preliminary data and Project interests, in the next Cycle, the Biomarker Core will measure Ab42, NT1 tau and NfL, vascular injury markers (especially VEGF-related molecules) and Th1 and Th2 inflammatory markers (e.g., IFN-g and IL-4 respectively) and other associated markers. It will also continue to identify, evaluate and implement novel technologies and biomarkers for HABS. Data generated will be quality-controlled and transferred to DataCentral in coordination with the Analytic Core for use in Projects 1-4.